sb 239063 has been researched along with Atherogenesis in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morris, JB | 1 |
| Olzinski, AR | 1 |
| Bernard, RE | 1 |
| Aravindhan, K | 1 |
| Mirabile, RC | 1 |
| Boyce, R | 1 |
| Willette, RN | 1 |
| Jucker, BM | 1 |
1 other study available for sb 239063 and Atherogenesis
| Article | Year |
|---|---|
p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment.
Topics: Angiotensin II; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Contrast Media; Enzyme Inhibitor | 2008 |